Free Trial
NASDAQ:ELAB

PMGC Q4 2025 Earnings Results & Report

PMGC logo
$2.90 -0.07 (-2.49%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PMGC reported Q4 2025 earnings on March 30, 2026. The company reported EPS of -$527.57, while revenue was $0.30 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

PMGC EPS Results

Actual EPS
-$527.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PMGC Revenue Results

Actual Revenue
$0.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

PMGC Q4 2025 Earnings FAQ

PMGC (NASDAQ:ELAB) reported earnings of -$527.57 per share for Q4 2025. The report was announced on Monday, March 30, 2026.

PMGC reported revenue of $0.30 million for Q4 2025.

PMGC Earnings Headlines

PMGC (NASDAQ:ELAB) Shares Down 1.6% - Here's What Happened
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
See More PMGC Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMGC? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMGC and other key companies, straight to your email.

About PMGC

Elevai Labs, Inc., formerly known as PMGC (NASDAQ:ELAB) Holdings, Inc., is a biotechnology and medical aesthetics company focused on developing and commercializing innovative skincare products and aesthetic treatments. The company combines biotechnology, regenerative medicine and cosmetic science to address skin health, rejuvenation and related aesthetic needs.

Elevai Labs’ product development activities include topical skincare formulations and professional-use products designed for aesthetic providers. Its offerings are intended to support procedures and treatments addressing concerns such as skin aging, texture and overall appearance. The company has also described a proprietary platform for developing and manufacturing aesthetic products, including formulations based on regenerative and extracellular vesicle technologies.

Elevai Labs markets its products primarily through medical aesthetics and skincare channels, including physicians, clinics and other professional providers. The company is headquartered in California and has focused on expanding its presence in the U.S. aesthetics market. As a development-stage company, its product portfolio and commercial strategy may continue to evolve.

View PMGC Profile